A Phase 2 interventional study of decitabine and decitabine in Myelodysplastic Syndrome, sponsored by Eisai Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-24.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 27th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 36 in phase 2, and was the 16th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 60+
Clinical Hub for Interventional Research (CHOIR) · Sites in Australia
Ages 18+
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 49 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 74 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 7 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing decitabine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923488West Virginia UniversityLeflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | 2027-10 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).
This is a randomized open-label Phase 2 efficacy and safety study of two (2) subcutaneous (SQ) dosing schedules of decitabine in subjects with Low or Intermediate 1 Risk MDS. This study will be conducted in up to 6 study centers in the United States.
The primary efficacy outcome is the overall improvement rate. These two doses will be administered subcutaneously. The probability that one schedule is superior to the other will be estimated, and the level of toxicity for each schedule will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet the following criteria to be enrolled in this study:
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: decitabine
Drug: decitabine
Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
Also known as: Dacogen
Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
Also known as: Dacogen
The Overall Improvement Rate
Defined as proportion of patients having complete remission (CR), partial remission (PR), marrow complete remission (mCR), or hematologic improvement. Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Remission: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 109/L; Neutrophils ≥ 1.0 X 109/Lb; Blasts 0%. Partial Remission: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by ≥ 50% over pretreatment but still \> 5%. Marrow Complete Remission: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR. HI Improvement: shown in increases in hemoglobin, platelet and neutrophil response.
Time frame: Up to one year
This study was recruited at 5 centers in U.S. during the period of Jun 2008 to Aug 2011.
| Milestone | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days |
|---|---|---|
| Started | 44 | 23 |
| Received at least 2 cycles of treatment | 43 | 22 |
| Completed | 11 | 4 |
| Not completed | 33 | 19 |
| Withdrew: Progressive disease | 7 | 5 |
| Withdrew: Allogeneic bone marrow transplantation | 2 | 1 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Emergence of clinically significant lab | 1 | 2 |
| Withdrew: Withdrawal by subject | 10 | 2 |
| Withdrew: Physician decision | 9 | 6 |
Defined as proportion of patients having complete remission (CR), partial remission (PR), marrow complete remission (mCR), or hematologic improvement. Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Remission: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 109/L; Neutrophils ≥ 1.0 X 109/Lb; Blasts 0%. Partial Remission: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by ≥ 50% over pretreatment but still \> 5%. Marrow Complete Remission: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR. HI Improvement: shown in increases in hemoglobin, platelet and neutrophil response.
| Percentage of Participants | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days |
|---|---|---|
| Overall Improvement Rate | 23.3 | 22.7 |
| Complete Response | 16.3 | 0 |
| Marrow Complete Response | 0 | 4.5 |
| Partial Response | 0 | 4.5 |
| Hematologic Improvement | 7.0 | 13.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Schedule A: SQ 3 Consecutive Days | — | 18/43 (41.9%) | 43/43 (100%) |
| Schedule B: SQ Once Every 7 Days | — | 10/22 (45.5%) | 22/22 (100%) |
| Event | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days |
|---|---|---|
| PneumoniaInfections and infestations | 1/43 | 2/22 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/43 | 0/22 |
| Abdominal painGastrointestinal disorders | 2/43 | 0/22 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 2/43 | 0/22 |
| AnemiaBlood and lymphatic system disorders | 0/43 | 1/22 |
| CellulitisInfections and infestations | 1/43 | 1/22 |
| SepsisInfections and infestations | 0/43 | 1/22 |
| PneumonitisInfections and infestations | 0/43 | 1/22 |
| AppendicitisInfections and infestations | 0/43 | 1/22 |
| Escherichia bacteremiaInfections and infestations | 0/43 | 1/22 |
| Event | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 27/43 | 15/22 |
| AnemiaBlood and lymphatic system disorders | 24/43 | 9/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 18/43 | 12/22 |
| LeukopeniaBlood and lymphatic system disorders | 18/43 | 10/22 |
| FatigueGeneral disorders | 17/43 | 10/22 |
| Decreaed appetiteMetabolism and nutrition disorders | 5/43 | 9/22 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 7/43 | 8/22 |
| PyrexiaGeneral disorders | 14/43 | 6/22 |
| NauseaGastrointestinal disorders | 12/43 | 3/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/43 | 3/22 |
Modified Intent to Treat (mITT) Population
| Age Continuous(years) | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days | Total |
|---|---|---|---|
| Mean | 66.9 ± 14.39 | 70.5 ± 9.86 | 68.2 ± 13.07 |
| Sex: Female, Male(Participants) | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days | Total |
|---|---|---|---|
| Female | 18 | 2 | 20 |
| Male | 25 | 20 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 42 | 20 | 62 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Schedule A: SQ 3 Consecutive Days | Schedule B: SQ Once Every 7 Days | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 0 | 5 |
| White | 35 | 20 | 55 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
The record gives a start of May 2008 and a primary completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine